Apimeds Pharmaceuticals US Inc. (APUS)
NYSE: APUSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
APUS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.96M
- EPS (TTM)
- -$12.69
- Dividend yield
- None
- 52-week range
- 1.51 – 59.70
- Day range
- 1.51 – 1.77
- Volume / Avg
- 48.55K / 3.73M
- Beta
- —
- Shares outstanding
- 1.85M
52-week range
APUS stock today
On Nov 20, APUS ended the session at $1.60, shedding $0.14 (8.05%), versus the S&P 500's 3.70% decline. Trading was light, with 48.55K shares changing hands, about 1% of the average daily volume. Shares are 97.3% below their 52-week high of $59.70, set on May 5, 2026 and 6.0% above the 52-week low of $1.51, near the bottom of the past year's range.
APUS is down 90.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 93.0%. Apimeds Pharmaceuticals US has posted a net loss over the last twelve months (EPS of -$12.69), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Apimeds Pharmaceuticals US
Company profileApimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Headquarters
- Matawan, NJ
- IPO year
- 2025
- Website
- mindwavedao.com
Financial highlights
Full financialsApimeds Pharmaceuticals US reported a net loss of $6.0 million, compared with a loss of $1.4 million a year earlier. Diluted earnings per share came in at -$0.55.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-6.00M | $-1.39M | $-777.69K |
| EPS (diluted) | $-0.55 | $-0.18 | $-0.17 |
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 16, 2026
- EPS actual vs est.
- $0.29 vs —
APUS news
All APUS news- Apimeds Pharmaceuticals US Reports Third Quarter 2026 Results, Delivers First Operating Revenue from Technology ServicesGlobeNewswire
- $NILA Token Now Trading on PICOL, Opening Access for Eligible Users in South KoreaGlobeNewswire
- NILA Token to Begin Trading on Pionex, Opening Access to Eligible Users WorldwideGlobeNewswire
- MindWave Innovations Signs 3 Client Network Agreements in 10 Days, Extending MindChain into Climate Finance, Sports Media and Insurance; Apimeds Pharmaceuticals US Provides Required NYSE American DisclosureGlobeNewswire
Apimeds Pharmaceuticals US peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| JAGXJaguar Health Inc. | 0.227 | -30.58% | $3.03M | vs APUS |
| SKYESkye Bioscience Inc. | 0.70 | -11.03% | $3.10M | vs APUS |
| GELSGelteq Limited | 0.2701 | -3.74% | $3.11M | vs APUS |
| AZTRAzitra Inc | 0.5168 | -2.75% | $3.13M | vs APUS |
| MDCXMedicus Pharma Ltd. | 1.14 | -2.16% | $3.16M | vs APUS |
| KPRXKiora Pharmaceuticals Inc. | 0.7202 | -12.28% | $3.19M | vs APUS |
| NRSNNeuroSense Therapeutics Ltd. | 1.28 | +1.59% | $3.19M | vs APUS |
| TRAWTraws Pharma Inc. | 0.175 | -23.91% | $2.69M | vs APUS |
Indexes, lists and sector
Apimeds Pharmaceuticals US stock FAQ
What is Apimeds Pharmaceuticals US's stock price today?
APUS last traded at $1.60 as of Nov 20, 4:00 PM EST, down 8.05% on the day. Prices are delayed at least 15 minutes.
Does Apimeds Pharmaceuticals US pay a dividend?
No. Apimeds Pharmaceuticals US does not currently pay a regular cash dividend.
Has APUS ever split its stock?
Yes. The most recent APUS stock split was a 1-for-10 split on Jul 24, 2026.
What is the APUS 52-week high?
The 52-week high for APUS is $59.70 and the 52-week low is $1.51. The stock is currently 97.3% below its high.